Procyon Advisors LLC Makes New Investment in Hologic, Inc. (NASDAQ:HOLX)

Procyon Advisors LLC acquired a new position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,208 shares of the medical equipment provider's stock, valued at approximately $692,000.

A number of other large investors have also recently bought and sold shares of HOLX. Principal Financial Group Inc. lifted its position in shares of Hologic by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock worth $19,547,000 after buying an additional 1,606 shares during the last quarter. Groupama Asset Managment raised its stake in Hologic by 63.4% during the fourth quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider's stock worth $3,918,000 after acquiring an additional 21,037 shares in the last quarter. Proficio Capital Partners LLC bought a new position in shares of Hologic in the fourth quarter worth about $4,215,000. Signaturefd LLC lifted its holdings in shares of Hologic by 34.5% in the fourth quarter. Signaturefd LLC now owns 2,940 shares of the medical equipment provider's stock worth $212,000 after acquiring an additional 754 shares during the last quarter. Finally, Brevan Howard Capital Management LP boosted its stake in shares of Hologic by 85.5% in the 4th quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider's stock valued at $1,401,000 after purchasing an additional 8,960 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have weighed in on HOLX. Morgan Stanley decreased their target price on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Royal Bank of Canada dropped their target price on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Finally, Citigroup lowered their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Twelve equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Hologic presently has a consensus rating of "Hold" and a consensus price target of $77.42.

Insider Buying and Selling at Hologic

In other news, Director Martin D. Madaus bought 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The stock was bought at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the purchase, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.88% of the company's stock.

Hologic Trading Down 1.1%

Shares of HOLX stock traded down $0.71 during mid-day trading on Wednesday, hitting $64.43. The company's stock had a trading volume of 1,684,424 shares, compared to its average volume of 2,300,771. The company has a market cap of $14.36 billion, a PE ratio of 20.33, a P/E/G ratio of 2.14 and a beta of 0.55. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The company's fifty day simple moving average is $58.42 and its 200-day simple moving average is $65.16. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The company's revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.03 earnings per share. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.